APA (7th ed.) Citation

IA, C., RI, C., CC, Y., TP, L., & CY, Y. (2026). Real-world comparative outcomes of darolutamide- versus abiraterone-based triplet therapy for metastatic hormone-sensitive prostate cancer: A retrospective cohort study. Therapeutic advances in urology, 18, 17562872261463076. https://doi.org/10.1177/17562872261463076

Chicago Style (17th ed.) Citation

IA, Chen, Chang RI, Yu CC, Lin TP, and Yang CY. "Real-world Comparative Outcomes of Darolutamide- Versus Abiraterone-based Triplet Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Cohort Study." Therapeutic Advances in Urology 18 (2026): 17562872261463076. https://doi.org/10.1177/17562872261463076.

MLA (9th ed.) Citation

IA, Chen, et al. "Real-world Comparative Outcomes of Darolutamide- Versus Abiraterone-based Triplet Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Cohort Study." Therapeutic Advances in Urology, vol. 18, 2026, p. 17562872261463076, https://doi.org/10.1177/17562872261463076.